207 related articles for article (PubMed ID: 20401670)
1. Efficacy of monoterpene perillyl alcohol upon survival rate of patients with recurrent glioblastoma.
da Fonseca CO; Simão M; Lins IR; Caetano RO; Futuro D; Quirico-Santos T
J Cancer Res Clin Oncol; 2011 Feb; 137(2):287-93. PubMed ID: 20401670
[TBL] [Abstract][Full Text] [Related]
2. Correlation of tumor topography and peritumoral edema of recurrent malignant gliomas with therapeutic response to intranasal administration of perillyl alcohol.
Da Fonseca CO; Silva JT; Lins IR; Simão M; Arnobio A; Futuro D; Quirico-Santos T
Invest New Drugs; 2009 Dec; 27(6):557-64. PubMed ID: 19139816
[TBL] [Abstract][Full Text] [Related]
3. Ras pathway activation in gliomas: a strategic target for intranasal administration of perillyl alcohol.
da Fonseca CO; Linden R; Futuro D; Gattass CR; Quirico-Santos T
Arch Immunol Ther Exp (Warsz); 2008; 56(4):267-76. PubMed ID: 18726148
[TBL] [Abstract][Full Text] [Related]
4. Preliminary results from a phase I/II study of perillyl alcohol intranasal administration in adults with recurrent malignant gliomas.
da Fonseca CO; Schwartsmann G; Fischer J; Nagel J; Futuro D; Quirico-Santos T; Gattass CR
Surg Neurol; 2008 Sep; 70(3):259-66; discussion 266-7. PubMed ID: 18295834
[TBL] [Abstract][Full Text] [Related]
5. Long-term outcome in patients with recurrent malignant glioma treated with Perillyl alcohol inhalation.
DA Fonseca CO; Teixeira RM; Silva JC; DE Saldanha DA Gama Fischer J; Meirelles OC; Landeiro JA; Quirico-Santos T
Anticancer Res; 2013 Dec; 33(12):5625-31. PubMed ID: 24324108
[TBL] [Abstract][Full Text] [Related]
6. Intranasal perillyl alcohol therapy improves survival of patients with recurrent glioblastoma harboring mutant variant for MTHFR rs1801133 polymorphism.
Faria GM; Soares IDP; D'Alincourt Salazar M; Amorim MR; Pessoa BL; da Fonseca CO; Quirico-Santos T
BMC Cancer; 2020 Apr; 20(1):294. PubMed ID: 32264844
[TBL] [Abstract][Full Text] [Related]
7. A phase II trial of erlotinib in patients with recurrent malignant gliomas and nonprogressive glioblastoma multiforme postradiation therapy.
Raizer JJ; Abrey LE; Lassman AB; Chang SM; Lamborn KR; Kuhn JG; Yung WK; Gilbert MR; Aldape KA; Wen PY; Fine HA; Mehta M; Deangelis LM; Lieberman F; Cloughesy TF; Robins HI; Dancey J; Prados MD;
Neuro Oncol; 2010 Jan; 12(1):95-103. PubMed ID: 20150372
[TBL] [Abstract][Full Text] [Related]
8. Recent advances in the molecular genetics of malignant gliomas disclose targets for antitumor agent perillyl alcohol.
da Fonseca CO; Landeiro JA; Clark SS; Quirico-Santos T; da Costa Carvalho Mda G; Gattass CR
Surg Neurol; 2006; 65 Suppl 1():S1:2-1:8; discussion S1:8-1:9. PubMed ID: 16427438
[TBL] [Abstract][Full Text] [Related]
9. Phase 2 trial of dasatinib in target-selected patients with recurrent glioblastoma (RTOG 0627).
Lassman AB; Pugh SL; Gilbert MR; Aldape KD; Geinoz S; Beumer JH; Christner SM; Komaki R; DeAngelis LM; Gaur R; Youssef E; Wagner H; Won M; Mehta MP
Neuro Oncol; 2015 Jul; 17(7):992-8. PubMed ID: 25758746
[TBL] [Abstract][Full Text] [Related]
10. Perillyl alcohol for the treatment of temozolomide-resistant gliomas.
Cho HY; Wang W; Jhaveri N; Torres S; Tseng J; Leong MN; Lee DJ; Goldkorn A; Xu T; Petasis NA; Louie SG; Schönthal AH; Hofman FM; Chen TC
Mol Cancer Ther; 2012 Nov; 11(11):2462-72. PubMed ID: 22933703
[TBL] [Abstract][Full Text] [Related]
11. Circulating Cell-Free DNA as a Prognostic and Molecular Marker for Patients with Brain Tumors under Perillyl Alcohol-Based Therapy.
Faria G; Silva E; Da Fonseca C; Quirico-Santos T
Int J Mol Sci; 2018 May; 19(6):. PubMed ID: 29848970
[TBL] [Abstract][Full Text] [Related]
12. Graded functional diffusion map-defined characteristics of apparent diffusion coefficients predict overall survival in recurrent glioblastoma treated with bevacizumab.
Ellingson BM; Cloughesy TF; Lai A; Mischel PS; Nghiemphu PL; Lalezari S; Schmainda KM; Pope WB
Neuro Oncol; 2011 Oct; 13(10):1151-61. PubMed ID: 21856685
[TBL] [Abstract][Full Text] [Related]
13. Second-line chemotherapy with irinotecan plus carmustine in glioblastoma recurrent or progressive after first-line temozolomide chemotherapy: a phase II study of the Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO).
Brandes AA; Tosoni A; Basso U; Reni M; Valduga F; Monfardini S; Amistà P; Nicolardi L; Sotti G; Ermani M
J Clin Oncol; 2004 Dec; 22(23):4779-86. PubMed ID: 15570079
[TBL] [Abstract][Full Text] [Related]
14. Analysis of EGF+61A>G polymorphism and EGF serum levels in Brazilian glioma patients treated with perillyl alcohol-based therapy.
da Silveira Fd; Lopes Bde A; da Fonseca CO; Quirico-Santos T; de Palmer Paixão IC; de Amorim LM
J Cancer Res Clin Oncol; 2012 Aug; 138(8):1347-54. PubMed ID: 22481252
[TBL] [Abstract][Full Text] [Related]
15. Biweekly fotemustine schedule for recurrent glioblastoma in the elderly: activity and toxicity assessment of a multicenter study.
Addeo R; Lamberti G; Simonetti G; Iodice P; Marinelli A; Montella L; Cappabianca S; Gaviani P; Caraglia M; Prete SD; Silvani A
CNS Oncol; 2019 Jun; 8(2):CNS32. PubMed ID: 31290692
[No Abstract] [Full Text] [Related]
16. Patupilone (epothilone B) for recurrent glioblastoma: clinical outcome and translational analysis of a single-institution phase I/II trial.
Oehler C; Frei K; Rushing EJ; McSheehy PM; Weber D; Allegrini PR; Weniger D; Lütolf UM; Knuth A; Yonekawa Y; Barath K; Broggini-Tenzer A; Pruschy M; Hofer S
Oncology; 2012; 83(1):1-9. PubMed ID: 22688083
[TBL] [Abstract][Full Text] [Related]
17. Phase II study of panobinostat in combination with bevacizumab for recurrent glioblastoma and anaplastic glioma.
Lee EQ; Reardon DA; Schiff D; Drappatz J; Muzikansky A; Grimm SA; Norden AD; Nayak L; Beroukhim R; Rinne ML; Chi AS; Batchelor TT; Hempfling K; McCluskey C; Smith KH; Gaffey SC; Wrigley B; Ligon KL; Raizer JJ; Wen PY
Neuro Oncol; 2015 Jun; 17(6):862-7. PubMed ID: 25572329
[TBL] [Abstract][Full Text] [Related]
18. Phase II study of bevacizumab and temsirolimus combination therapy for recurrent glioblastoma multiforme.
Lassen U; Sorensen M; Gaziel TB; Hasselbalch B; Poulsen HS
Anticancer Res; 2013 Apr; 33(4):1657-60. PubMed ID: 23564811
[TBL] [Abstract][Full Text] [Related]
19. The relationship between six-month progression-free survival and 12-month overall survival end points for phase II trials in patients with glioblastoma multiforme.
Ballman KV; Buckner JC; Brown PD; Giannini C; Flynn PJ; LaPlant BR; Jaeckle KA
Neuro Oncol; 2007 Jan; 9(1):29-38. PubMed ID: 17108063
[TBL] [Abstract][Full Text] [Related]
20. A phase I/II trial of vandetanib for patients with recurrent malignant glioma.
Kreisl TN; McNeill KA; Sul J; Iwamoto FM; Shih J; Fine HA
Neuro Oncol; 2012 Dec; 14(12):1519-26. PubMed ID: 23099652
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]